Zobrazeno 1 - 10
of 629
pro vyhledávání: '"Darolutamide"'
Autor:
Junichi Ikeda, Hisanori Taniguchi, Hiroki Takayama, Yuki Masuo, Takahiro Nakamoto, Katsunori Uchida, Hidefumi Kinoshita
Publikováno v:
IJU Case Reports, Vol 7, Iss 6, Pp 459-462 (2024)
Introduction Neuroendocrine prostate cancer is an aggressive histological subtype of prostate cancer with a poor prognosis. Neuroendocrine prostate cancer is traditionally treated with cisplatin‐based chemotherapy, similar to that used in treating
Externí odkaz:
https://doaj.org/article/6d799244b3224637bb13ef0c326b5499
Autor:
Motohide Uemura, Hiroaki Kikukawa, Yasuhiro Hashimoto, Hiroji Uemura, Atsushi Mizokami, Masashi Kato, Hisashi Matsushima, Takeo Kosaka, Motonobu Nakamura, Satoshi Fukasawa, Matthew R. Smith, Bertrand Tombal, Maha Hussain, Fred Saad, Karim Fizazi, Cora N. Sternberg, E. David Crawford, Haruka Kakiuchi, Masanao Akiyama, Rui Li, Iris Kuss, Heikki Joensuu, Hiroyoshi Suzuki
Publikováno v:
Cancer Medicine, Vol 13, Iss 21, Pp n/a-n/a (2024)
Abstract Background In the global ARASENS study (NCT02799602), darolutamide plus androgen‐deprivation therapy (ADT) and docetaxel significantly reduced risk of death by 32.5% versus placebo plus ADT and docetaxel (hazard ratio [HR] 0.68; 95% confid
Externí odkaz:
https://doaj.org/article/1058407c6e5d4f8494ab24581515bb95
Autor:
Syeda Afshan, Yu Gang Kim, Jesse Mattsson, Malin Åkerfelt, Pirkko Härkönen, Martin Baumgartner, Matthias Nees
Publikováno v:
Cancer Medicine, Vol 13, Iss 18, Pp n/a-n/a (2024)
Abstract Background Inhibition of androgen receptor (AR) signaling is the main treatment strategy in advanced prostate cancer (PCa). A subset of castration resistant prostate cancer (CRPC) bypasses the AR blockade by increased fibroblast growth facto
Externí odkaz:
https://doaj.org/article/50bad1de5a494228b47b0e9e0c70543a
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 5, Iss 3, Pp 543-550 (2024)
Antiandrogens have been used for the treatment of prostate cancer as a single agent or in combination with hormone deprivation therapy. New generation antiandrogens act like androgen receptor inhibitors (ARIs). Their binding complex blocks the pathwa
Externí odkaz:
https://doaj.org/article/d16ce22b5d594bbc955af0adc657912a
Publikováno v:
Chinese Journal of Magnetic Resonance, Vol 41, Iss 1, Pp 56-66 (2024)
Darolutamide is an important drug for the treatment of prostate cancer. When studying its synthesis process, three impurities A, B, and C were discovered and purified in the first step of Suzuki coupling and the second step of hydrolysis deprotection
Externí odkaz:
https://doaj.org/article/ccc61a644a014e73acebd73007468bf4
Publikováno v:
Research and Reports in Urology, Vol Volume 15, Pp 509-517 (2023)
Margaret F Meagher,1 Amirali Salmasi,1 Tyler F Stewart2 1Department of Urology, University of California San Diego, La Jolla, CA, USA; 2Division of Hematology-Oncology and BMT, University of California San Diego, La Jolla, CA, USACorrespondence: Tyle
Externí odkaz:
https://doaj.org/article/485dd4a85c9845f1ba9029eed447432d
Autor:
Darren M. C. Poon, Guang-Ming Tan, Kuen Chan, Marco T. Y. Chan, Tim-Wai Chan, Raymond W. M. Kan, Martin H. C. Lam, Clarence L. H. Leung, Kenneth C. W. Wong, Kevin K. H. Kam, Chi-Fai Ng, Peter K. F. Chiu
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundAndrogen deprivation therapy (ADT) is the foundational treatment for metastatic prostate cancer (PCa). Androgen receptor (AR) axis-targeted therapies are a new standard of care for advanced PCa. Although these agents have significantly impr
Externí odkaz:
https://doaj.org/article/647ec4050db24cd28b254ed2c3cf2112
Publikováno v:
Current Oncology, Vol 30, Iss 4, Pp 4365-4378 (2023)
The treatment paradigm for metastatic castrate-sensitive prostate cancer (mCSPC) has evolved rapidly in the past decade with the approval of several life-prolonging therapies including docetaxel chemotherapy and multiple androgen receptor pathway inh
Externí odkaz:
https://doaj.org/article/2e0b7de9951a441aaf42bb019fa08cbf
Autor:
Cheng-Kuang Yang, Tai-Lung Cha, Yen-Hwa Chang, Shu-Pin Huang, Jen-Tai Lin, Shian-Shiang Wang, Chao-Yuan Huang, See-Tong Pang
Publikováno v:
Journal of the Formosan Medical Association, Vol 122, Iss 4, Pp 299-308 (2023)
Darolutamide, a second-generation androgen receptor inhibitor (SGARI), has been shown to increase metastasis-free survival and overall survival among men with non-metastatic castration-resistant prostate cancer (nmCRPC). Its unique chemical structure
Externí odkaz:
https://doaj.org/article/22218bd7913b43608c342fda22f84441
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.